Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Gefenaite, Giedre ^a,b   Tacken, Margot ^c   Bos, Jens ^a   Stirbu Wagner, Irina ^d   Korevaar, Joke C ^d   Stolk, Ronald P ^b   Wolters, Bert ^e   Bijl, Marc ^f   Postma, Maarten J ^a,b   Wilschut, Jan ^b   Nichol, Kristin L ^g,h   Hak, Eelko ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^e Regional Health Services   (Netherlands)

^f MARTINI HOSPITAL   (Netherlands)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H1N1)PDM09; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; RETROSPECTIVE STUDY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NETHERLANDS; POLYSORBATES; RETROSPECTIVE STUDIES; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84879269590     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066125     Document Type: Article

References (30)

1. Donker GA (2011) Continuous Morbidity Registration at Dutch Sentinel General Practice Network 2009. NIVEL, Utrecht 2011.
2. Steens A, Wijnans EG, Dieleman JP, Sturkenboom MC, van der Sande MA, et al. (2011) Effectiveness of a MF-59TM-adjuvanted pandemic influenza vaccine to prevent 2009 influenza A/H1N1-related hospitalisation; a matched case-control study. BMC Infec Dis 11: 196.
3. FluNet, Global Influenza Surveillance and Response System (GISRS) (2013) Number of specimens positive for influenza by subtype. Generated 10 April 2013.
4. Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, et al. (2012) Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Vaccine 30: 5030-5037.
5. Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, et al. (2011) Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol 18: 1358-1364.
6. Valenciano M, Kissling E, Cohen J, Oroszi B, Barret A-, Rizzo C, et al. (2011) Estimates of pandemic influenza vaccine effectiveness in europe, 2009-2010: Results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 8: e100038.
7. Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, et al. (2011) Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 6: e23085.
8. Wu J, Xu F, Lu L, Lu M, Miao L, et al. (2012) Safety and Effectiveness of a 2009 H1N1 Vaccine in Beijing (2010). N Engl J Med 363: 2416-23.
9. Ortqvist A, Berggren I, Insulander M, de Jong B, Svenungsson B, (2011) Effectiveness of an Adjuvanted Monovalent Vaccine Against the 2009 Pandemic Strain of Influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis 52: 1203-11.
10. Andrews N, Waight P, Yung CF, Yung CF, Miller E, (2011) Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 203: 32-9.
11. Castilla J, Moran J, Martinez-Artola V, Fernandez-Alonso M, Guevara M, et al. (2011) Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: Cohort and case-control study. Vaccine 29: 5919-5924.
12. Steens A, van der Hoek W, Dijkstra F, van der Sande M, (2011) Influenza vaccine effectiveness, 2010/11. Euro Surveill 16: 19843.
13. Wet bescherming persoonsgegevens. Available: Http://wetten overheid nl/BWBR0011468/geldigheidsdatum_01-08-2012. Accessed 1 August 2012.
14. WMA Declaration of Helsinki- Ethical Principles for Medical Research Involving Human Subjects. Available: Http://www wma net/en/30publications/10policies/b3/. Accessed 1 August 2012.
15. Tacken MAJB, Jansen B, Mulder J, Visscher S, Heijnen MLA, et al. (2013) Pandemic influenza A(H1N1)pdm09 improves vaccination routine in subsequent years: A cohort study from 2009 to 2011. Vaccine 31: 900-905.
16. EMEA (2010) Annex I Summary of Product characteristics: Focetria.
17. Lamberts H, Hofmans-Okkes I, (1996) The core of computer based patient records in family practice: episodes of care classified with ICPC. International journal of bio-medical computing 42: 35-41.
18. Weiner MG, Xie D, Tannen RL, (2008) Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding. Pharmacoepidemiol Drug Saf 17: 661-670.
19. Tacken M, Mulder J, Visscher S, Tiersma W, Donkers J, et al. (2010) Monitoring vaccinatiegraad Nationaal Programma Grieppreventie 2009 LINH & IQ Scientific Institute for Quality of Healthcare.
20. CDC (2009) Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR. Morbidity and mortality weekly report 58: 521-524.
21. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361: 1945-52.
22. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
23. Wong K, Campitelli MA, Stukel TA, Kwong JC, (2012) Estimating Influenza Vaccine Effectiveness in Community-Dwelling Elderly Patients Using the Instrumental Variable Analysis Method. Arch Intern Med 172: 484-91.
24. Groenwold RHH, Hoes AW, Hak E, (2009) Impact of influenza vaccination on mortality risk among the elderly. Eur Resp J 34: 56-62.
25. Soler J, Okkes I, Wood M, Lamberts H, (2008) The coming of age of ICPC: celebrating the 21st birthday of the International Classification of Primary Care. Fam Pract 25: 312-317.
26. Rodríguez-Rieiro C, Domínguez-Berjón MF, Esteban-Vasallo MD, Sánchez-Perruca L, Astray-Mochales J, et al. (2010) Vaccination coverage against 2009 seasonal influenza in chronically ill children and adults: analysis of population registries in primary care in Madrid (Spain). Vaccine 28: 6203-6209.
27. Rahamat-Langendoen JC, Tutuhatunewa ED, Scholvinck EH, Hak E, Koopmans M, et al. (2012) Influenza in the immediate post-pandemic era: A comparison with seasonal and pandemic influenza in hospitalized patients. J Clin Virol 54: 135-40.
28. McElhaney JE, (2011) Influenza vaccine responses in older adults. Ageing Res Rev 10: 379-88.
29. Health Council of the Netherlands (2009) Vaccinatie tegen pandemische influenza A/H1N1 2009: Doelgroepen en prioritering. Available: Http://www.gezondheidsraad.nl/sites/default/files/200910_0.pdf. Accessed 15 June 2010.
30. Health Council of the Netherlands (2007) Griepvaccinatie: Herziening van de indicatiestelling. Availbale: Http://www.gezondheidsraad.nl/sites/default/files/2007@09N.pdf. Accessed 15 June 2010.